What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
TheDaoIndex KDAO2011
3 years 6 months ago
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
Richard Conway RichardPAConway
3 years 6 months ago
Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
David Liew drdavidliew
3 years 6 months ago
TNFi were going to unleash a TB wave
What has the biologic era really done for TB & opportunistic infx?
Hospitalised data from Western Australia post-2003:
TB actually not up (screening)
myocoses were up (no screening)
Dare I say it: screening works
OP0274 #EULAR2022 @RheumNow
Dr. John Cush RheumNow
3 years 6 months ago
#EULAR2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.
https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0256 by @CaoilfhionnMD, @DrLisaCS, @JuliePaikMD from @HopkinsRheum
10% of pts seronegative for COVID antibodies after vaccination
⭐️Risk factors: Non-white, J&J vaccine, MMF, RTX, GC, combination Rx, not-withholding peri-vaccination immunosuppression
@Rheumnow https://t.co/Izd4QJlOWH
TheDaoIndex KDAO2011
3 years 6 months ago
OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow
Richard Conway RichardPAConway
3 years 6 months ago
Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0278:
Increase in risk of CVA compared to general population ~1.2x risk
⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era
⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop
@Rheumnow https://t.co/r8QsJABfvx
Richard Conway RichardPAConway
3 years 6 months ago
Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI
Richard Conway RichardPAConway
3 years 6 months ago
Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS
David Liew drdavidliew
3 years 6 months ago
Can we predict VTEs from JAKi for RA at all?
Baseline elevated D-dimer pts who go on to develop VTE
(but not baseline CRP, so not just general inflamm)
Questions raised about effect modification for VTE following JAKi too. This story not yet done
OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors
⭐️118 pts w MSK complaints
76% w arthralgias/myalgias, 30% with inflammatory rheumatic features
Most grade 1/2, 2 grade 4 (myositis)
23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study
@RheumNow https://t.co/SINqmmjsLq
Richard Conway RichardPAConway
3 years 6 months ago
Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
Poster Hall